CLINICAL RESEARCH STUDY
AZURE Study
Join the AZURE Study — helping protect hearts and blood vessels through investigational research.
We are conducting a Phase III clinical research study to find out whether an investigational medication can lower the risk of serious heart and blood vessel problems — such as heart attack or stroke — in people who already have atherosclerotic cardiovascular disease (ASCVD) or are at high risk for developing it.
Study highlights at a glance
STUDY PHASE
Phase III — a late-stage clinical trial with many participants to confirm effectiveness and gather safety information.
WHO CAN JOIN
Adults with existing ASCVD or those at high risk of their first cardiovascular event.
Who may qualify if you have
Established ASCVD such as a previous heart attack, angina, stroke, or peripheral artery disease (PAD) — or if you are at high risk for a first cardiovascular event due to diabetes, high blood pressure, smoking, chronic kidney disease, or being overweight. Must be 18 years of age or older.
Why this study matters
If you're living with ASCVD or at elevated risk for significant cardiovascular events, this study offers access to a new investigational treatment in a carefully monitored environment. Your participation could help improve future care for people at risk — and you'll receive close medical attention throughout the process.
COMPENSATION
Up to $1,600
Or more if you qualify for the study
